New cancer clinical trial: The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor

Published on: April 23, 2018 at 12:00PM
Conditions:   Doxorubicin Adverse Reaction;   Cardiomyopathies, Secondary;   Breast Cancer
Intervention:  
Sponsor:   Rush University Medical Center
Recruiting
https://ift.tt/2qTCCsr